DJIA 16,408.54 -16.31 -0.10%
NASDAQ 4,095.52 0.00 0.00%
S&P 500 1,864.85 2.54 0.14%
market minute promo

2.34 -0.01 (-0.43%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CYTX $2.34 -0.43%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.35
Previous Close $2.35
Daily Range $2.30 - $2.46
52-Week Range $2.00 - $3.93
Market Cap $176.5M
P/E Ratio -6.00
Dividend (Yield) $0.00 (0.0%)
Volume 215,247
Average Daily Volume 567,966
Current FY EPS -$0.35

Sector

Healthcare

Industry

Drugs

Cytori Therapeutics, Inc. (USA) (CYTX) Description

A developing company which seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious, chronic, and life threatening conditions. Website: http://www.cytori.com/

News & Commentary Rss Feed

Fast and Furious Health Care Stocks This Week

MannKind, Cytori Therapeutics, and Omeros are among the health care stocks soaring this week.

Cytori Announces Senior Management Changes; Christopher Calhoun CEO and Director of Cytori Therapeut

Cytori Announces Senior Management Changes; Christopher Calhoun CEO and Director of Cytori Therapeutics, is Retiring as CEO of the Company, Effective Immediately

4 Stocks Under $10 Triggering Breakouts

Cytori Therapeutics: Global Patient Stem Cell Demand Builds, Important Short-Term Catalysts Ahead

Cytori Therapeutics Is A Cell Therapy Company With Several Positive Catalysts For 2014

A Glimpse At Our Small Cap Biotechnology Portfolio

Athersys: Why Did Shareholders Come Knocking At The Door Once Again?

Cytori Therapeutics Inc. (CYTX) Shares March Higher, Can It Continue? - Tale of the Tape

Cytori Therapeutics Inc. (CYTX) Shares March Higher, Can It Continue? - Tale of the Tape

Vical Incorporated (VICL) Jumps: Stock Up 14.5% - Tale of the Tape

Incyte (INCY) Jumps: Stock Rises 6.8% - Tale of the Tape

Cytori Receives IDE Approval from FDA to Initiate US Clinical Trial of Adipose-Derived Regenerative

Cytori Receives IDE Approval from FDA to Initiate US Clinical Trial of Adipose-Derived Regenerative Cells in Hamstring Injuries

See More CYTX News...

CYTX's Top Competitors

CYTX $2.34 (-0.43%)
Current stock: CYTX
AMGN $115.46 (-0.07%)
Current stock: AMGN
GILD $70.00 (1.04%)
Current stock: GILD
BIIB $290.54 (-0.32%)
Current stock: BIIB